Fate Therapeutics, Inc.

FATENASDAQ • USD
ThemeHealthcare - Oncology›Cell & Gene Therapy for Cancer
2.40 USD
↗ 0.05 (2.30%)🟢LIVE (AS OF 02:14 PM EDT)
🟢Market: OPEN

Fate Therapeutics, Inc. (FATE) is currently trading at $2.40. Technical and fundamental signals converge bearish — technicals rate "Sell" while fundamentals read "Strong Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On valuation, FATE trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Sep 15, 2026.

Open?$2.35
High?$2.44
Low?$2.32
Prev. Close?$2.35
Volume?557.6K
Avg. Volume?1.7M
VWAP?$2.39
Rel. Volume?0.33x
Bid / Ask
Bid?$2.40 × 600
Ask?$2.41 × 200
Spread?$0.01
Midpoint?$2.41
Valuation & Ratios
Market Cap?281.6M
Shares Out?119.8M
Float?99.1M
Float %?85.0%
P/E Ratio?N/A
P/B Ratio?1.84
EPS?-$1.05
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Themes
Healthcare - Oncology›Cell & Gene Therapy for CancerBiotech - Drug Development›Immunology & Autoimmune
Employees
161
Market Cap
281.6M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.fatetherapeutics.com
Listed
2013-10-01
Address
12278 SCRIPPS SUMMIT DRIVE
SAN DIEGO, CA 92131
Phone: 858.875.1803
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookStrong Sell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
0
Momentum?
17
Short Sent.?
29
Piotroski F-Score?2/9Weak
Altman Z-Score?-8.08Distress
Confidence?71%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?9.19%Elevated
Short Interest?9.1M
Days to Cover?6.2
Free Float99.1M
Avg Daily Volume1.5M
Settlement Date2026-08-31
Financial Health
Current Ratio?4.85Strong
Quick Ratio?4.85Strong
Cash Ratio?0.99Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
79
1.84CHEAP▾
P/S?
Peers
100
S&P
3
43.38HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.1CHEAP▾
EV/Sales?
Peers
100
S&P
3
38.38HIGH▾
Returns & Efficiency
ROE?
S&P
3
-82.1%WEAK▾
ROA?
S&P
3
-48.4%WEAK▾
Cash Flow & Enterprise
FCF?$-105658000
Enterprise Value?$249.1M
Fundamentals ratios updated end of day
MarketsMoversWatchlist